Seres <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 1b Data for SER-155 in Reducing Bloodstream Infections in Allogeneic Stem Cell Transplant Patients, Plans Phase 2 Trial
Seres Therapeutics Inc. announced that new post hoc data from its SER-155 Phase 1b trial will be presented at IDWeek 2025, scheduled for October 19-22 in Atlanta, Georgia. The oral presentation will cover clinical and microbiological outcomes of bloodstream infections (BSI) in adults undergoing allogeneic hematopoietic stem cell transplant, based on results from a randomized, double-blind, placebo-controlled study. According to the company, SER-155 was associated with a 77% reduction in BSIs, as well as lowered systemic antibiotic use and rates of febrile neutropenia compared to placebo. The presentation, which will include data on BSI pathogens, clinical outcomes, prophylaxis, and antimicrobial resistance patterns, is set for October 20. Seres Therapeutics is finalizing plans for a Phase 2 study of SER-155 following feedback from the FDA.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544542-en) on October 14, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。